Interaction of calcium antagonists with cyclic AMP phosphodiesterases and calmodulin.
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000378:metabolism*; D000818:Animals; D001921:Brain / Q000201:enzymology*; D002118:Calcium / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002135:Calcium-Binding Proteins / Q000378:metabolism*; D002147:Calmodulin / Q000378:metabolism*; D002645:Chickens; D003600:Cytosol / Q000201:enzymology; D004285:Dogs; D006801:Humans; D007668:Kidney / Q000201:enzymology; D007700:Kinetics; D008214:Lymphocytes / Q000201:enzymology; D009206:Myocardium / Q000201:enzymology*; D009529:Nicardipine; D009539:Nicotinic Acids / Q000494:pharmacology*; D009543:Nifedipine / Q000031:analogs & derivatives / Q000494:pharmacology*; D009553:Nimodipine; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D013050:Spectrometry, Fluorescence
D002121:Calcium Channel Blockers; D002135:Calcium-Binding Proteins; D002147:Calmodulin; D009539:Nicotinic Acids; D011725:Pyridines; D009553:Nimodipine; D009529:Nicardipine; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D009543:Nifedipine; D002118:Calcium